Evidence mapPaperPMID 41750311Full record

ReviewBiomolecules2026

AGE-RAGE Axis Involvement in Allergies and Autoimmunity: Cellular Signaling, Barrier Dysfunction and Immune Polarization.

Enrica Dato, Alessandra Ventre, Marilena Di Salvo, Federica Nuccio, Marco Casciaro, Sebastiano Gangemi

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Enrica DatoDepartment of Clinical and Experimental Medicine, Unit and School of Allergy and Clinical Immunology, University Hospital of Messina, University of Messina, 98125 Messina, Italy.
Alessandra VentreDepartment of Clinical and Experimental Medicine, Unit and School of Allergy and Clinical Immunology, University Hospital of Messina, University of Messina, 98125 Messina, Italy.
Marilena Di SalvoDepartment of Clinical and Experimental Medicine, Unit and School of Allergy and Clinical Immunology, University Hospital of Messina, University of Messina, 98125 Messina, Italy.
Federica NuccioDepartment of Clinical and Experimental Medicine, Unit and School of Allergy and Clinical Immunology, University Hospital of Messina, University of Messina, 98125 Messina, Italy.ORCID 0009-0009-0974-4755
Marco CasciaroDepartment of Medical Sciences, Unit and School of Allergy and Clinical Immunology, University Hospital of Messina, 98125 Messina, Italy.ORCID 0000-0002-5436-1501
Sebastiano GangemiDepartment of Clinical and Experimental Medicine, Unit and School of Allergy and Clinical Immunology, University Hospital of Messina, University of Messina, 98125 Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced glycation end-products (AGEs) are a variety of endogenous and exogenous substances that play an important role in inflammation, allergies, and autoimmune diseases. AGEs' pathogenicity, alongside advanced oxidation protein products (AOPPs) and other ligands, lies in their ability to bind the receptor for advanced glycation end-products (RAGE) and trigger pro-inflammatory signaling pathways and cytokine release. The literature reports numerous studies on the role of the AGE-RAGE axis in various allergic conditions, including bronchial asthma, atopic dermatitis, food allergies, and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, or Hashimoto's thyroiditis, where the significant role of the AGE-RAGE axis in the immunopathogenesis of both allergic and autoimmune conditions is largely discussed and demonstrated. They suggest promising opportunities for the development of new diagnostic markers and targeted therapeutic strategies. However, further large-scale studies are needed to fully understand this multifaceted pathway and translate these insights into effective clinical interventions.

Indexed as

Autoimmune DiseasesAutoimmunityGlycation End Products, AdvancedHypersensitivityReceptor for Advanced Glycation End ProductsAnimalsHumansSignal TransductionGlycation End Products, AdvancedReceptor for Advanced Glycation End Productsadvanced glycation end-productsAGE-RAGE axisallergyAOPPatopyautoimmunitychronic inflammationimmune dysregulationoxidative stresssRAGE

Identifiers

PMID41750311
PMCPMC12938222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.